Poliovirus Receptor Antikörper (PerCP-Cy5.5)

Produktnummer ABIN2659976

Dieses Anti-Poliovirus Receptor-Antikörper ist ein Ratte Monoklonal-Antikörper zur Detektion von Poliovirus Receptor in ELISPOT (Detection) und ELISA (Detection). Geeignet für Maus.

Kurzübersicht für Poliovirus Receptor Antikörper (PerCP-Cy5.5) (ABIN2659976)

Target: Poliovirus Receptor (PVR)

Reaktivität: Maus

Wirt: Ratte

Klonalität: Monoklonal

Konjugat: Dieser Poliovirus Receptor Antikörper ist konjugiert mit PerCP-Cy5.5

Applikation: ELISpot (Detection) (ELISPOT (Detection)), ELISA (Detection)

Klon: TX56

Produktdetails anti-Poliovirus Receptor Antikörper (PerCP-Cy5.5)

Aufreinigung: The antibody was purified by affinity chromatography and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.

Isotyp: IgG2a kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from prolonged exposure to light. Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu Poliovirus Receptor

Target: Poliovirus Receptor (PVR)

Andere Bezeichnung: CD155

Hintergrund: Mouse CD155, also known as homolog of polivirus receptor (PVR), is the founding member of a subfamily of immunoglobulin-like adhesion receptors (nectins). Mouse CD155 is expressed on a wide variety of cells of hematopoietic origin apart from its existence on the epithelial cells. The engagement of CD155 with CD226 and CD96 induces cytotoxicity of NK cells and CTL.

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cell-Cell Junction Organization, Cancer Immune Checkpoints, SARS-CoV-2 Protein Interaktom